Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Publications indexed to the term Leukemia, Experimental

1NrasG12D oncoprotein inhibits apoptosis of preleukemic cells expressing Cbfβ-SMMHC via activation of MEK/ERK axis. (Xue L, Pulikkan JA, Valk PJ, Castilla LH) Blood 2014 Jul 17;124(3):426-36       16 Citations
1IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy. (Labbe A, Nelles M, Walia J, Jia L, Furlonger C, Nonaka T, Medin JA, Paige CJ) J Cell Mol Med 2009 Aug;13(8B):1962-76       15 Citations
1Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. (Xia G, Truitt RL, Johnson BD) Biol Blood Marrow Transplant 2006 Apr;12(4):397-407       50 Citations
1A NotI-EcoRV promoter library for studies of genetic and epigenetic alterations in mouse models of human malignancies. (Yu L, Liu C, Bennett K, Wu YZ, Dai Z, Vandeusen J, Opavsky R, Raval A, Trikha P, Rodriguez B, Becknell B, Mao C, Lee S, Davuluri RV, Leone G, Van den Veyver IB, Caligiuri MA, Plass C) Genomics 2004 Oct;84(4):647-60       22 Citations
1Donor natural killer (NK1.1+) cells do not play a role in the suppression of GVHD or in the mediation of GVL reactions after DLI. (Johnson BD, Dagher N, Stankowski WC, Hanke CA, Truitt RL) Biol Blood Marrow Transplant 2001;7(11):589-95       11 Citations
1Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. (Johnson BD, Becker EE, Truitt RL) Biol Blood Marrow Transplant 1999;5(3):123-32       51 Citations
1Delayed infusion of immunocompetent donor cells after bone marrow transplantation breaks graft-host tolerance allows for persistent antileukemic reactivity without severe graft-versus-host disease. (Johnson BD, Truitt RL) Blood 1995 Jun 01;85(11):3302-12       129 Citations
1Use of anti-CD3 epsilon F(ab')2 fragments in vivo to modulate graft-versus-host disease without loss of graft-versus-leukemia reactivity after MHC-matched bone marrow transplantation. (Johnson BD, McCabe C, Hanke CA, Truitt RL) J Immunol 1995 May 15;154(10):5542-54       40 Citations
2Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. (Johnson BD, Drobyski WR, Truitt RL) Bone Marrow Transplant 1993 Apr;11(4):329-36       127 Citations
1A decrease in graft-vs.-host disease without loss of graft-vs.-leukemia reactivity after MHC-matched bone marrow transplantation by selective depletion of donor NK cells in vivo. (Johnson BD, Truitt RL) Transplantation 1992 Jul;54(1):104-12       49 Citations
1Distribution of Lyb-4.1 and other membrane antigens on murine lymphoid tumors. (Howe RC, Nelson RS, Rogan KM, Ahmed A, Aiken JJ, Dorf ME, Scherer JC, Sell KW, Humphreys RE) J Natl Cancer Inst 1979 Aug;63(2):375-8       2 Citations
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a